Delivery Order HHSN261201200018I-HHSN26100005

The National Cancer Institute issued a delivery order to The Institute For Cancer Research on September 15, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT) IDIQ for preclinical efficacy and intermediate endpoint biomarker studies supporting a nano-drug for colon cancer prevention, with a ceiling value of $1.57 million and ultimate completion date of June 14, 2026. PREVENT is a National Cancer Institute IDIQ structured around three technical pools: Preclinical Efficacy...

The National Cancer Institute awarded a firm fixed-price delivery order valued at $1,038,958 to The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, on July 10, 2023, for research on colorectal cancer prevention using urolithin A in rodent cancer models. The work will be performed in Philadelphia, Pennsylvania, with a completion date of July 9, 2027. This task order was issued without set-aside designation and falls under ICR's larger $149.995 million Indefinite...

The National Cancer Institute issued a delivery order to The Institute For Cancer Research on May 18, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT), a multiple-award indefinite delivery contract with a $1.24 million ceiling for this order. PREVENT is the National Cancer Institute's structured preclinical drug development vehicle supporting candidate chemopreventive and immunopreventive regimens across three technical pools: Preclinical Efficacy and Biomarkers,...

The National Cancer Institute issued a delivery order to the University of Illinois on July 1, 2020, with a ceiling value of $1,683,322.63 for preclinical efficacy and biomarker endpoint studies using carnosic acid and VIVOX40 for breast cancer prevention, under the PREVENT Preclinical Drug Development Program. PREVENT is the parent Indefinite Delivery Contract supporting the National Cancer Institute's preclinical drug development research initiatives. The delivery order is firm fixed price....

This federal contract award was made by the National Cancer Institute, a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Preclinical Drug Development Program (PREVENT). The $1,498,585.64 task order is for the research and development of a novel EPA analogue TP-252 and naproxen for colorectal cancer prevention in familial adenomatous polyposis (FAP) and Lynch syndrome models. The contract has no set-aside designation. UAB has performed numerous federal...

The National Institutes of Health National Human Genome Research Institute awarded Metabolon, Inc. a $53,420 fixed-price purchase order to conduct fecal metabolomic profiling of individuals of African descent with metabolic disorders. The work will be performed in Morrisville, North Carolina over a one-year period ending August 2024. Through this contract, Metabolon will analyze stool samples to develop metabolic profiles for research participants, as requested in the original solicitation...

This is a delivery order award under the National Cancer Institute's PREVENT Preclinical Drug Development Program, a $149,995,000 indefinite-delivery, indefinite-quantity (IDIQ) contract. The award, valued at $878,817.03, is for a task order titled "Preventing Colorectal Cancer Using TRAIL-Inducing ONC201 Alone or in Combination with NSAID." The prime contractor is the University of Oklahoma Health Sciences Center, a state-funded public research university with significant federal...

This is a delivery order issued under the National Cancer Institute's PREVENT Cancer Program (PREVENT) contract. The order, valued at $834,263.00, was awarded to the University of Oklahoma Health Sciences Center (OUHSC) to determine the potential clinical usefulness of aspirin and naproxen (another NSAID) for prostate cancer prevention using preclinical models. The University of Colorado-Denver is a subcontractor supporting this research. The award has a period of performance from July 2016 to...

The National Cancer Institute issued a delivery order to the University of Oklahoma (operating as the Board of Regents of the University of Oklahoma Health Sciences Center) on September 21, 2020, under the PREVENT Preclinical Drug Development Program IDIQ, with a ceiling value of $780,910.07 for preclinical efficacy studies on urinary bladder cancer prevention using everolimus and naproxen in combination. The PREVENT Preclinical Drug Development Program is a National Cancer Institute IDIQ...

This is a $521,214.97 Firm Fixed Price delivery order awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Oklahoma Health Sciences Center to conduct research on the chemoprevention of colorectal cancer with olmesartan medoxomil. The order is part of the NIH's PREVENT Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers for cancer prevention. The delivery order does not have a set-aside designation. University...